PW Medtech Group has the GF Score of 82, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes PW Medtech Group
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
PW Medtech Group (FRA:PWE) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
PW Medtech Group GF Score Related Terms
FRA:PWE vs ISRG, BDX, MDLN: GF Score Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's GF Score distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's GF Score falls into.
PW Medtech Group (FRA:PWE) has a GF Score of 82 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PW Medtech Group and its competitors. This is 28% above median its historical median of 64.00. Over the past decade, PW Medtech Group's GF Score has ranged from 31.00 to 93.00.
Is PW Medtech Group's GF Score too high?
PW Medtech Group's current GF Score of 82 is 28% above median its 10-year median of 64.00. Over the past 10 years, this metric has ranged from a low of 31.00 to a high of 93.00. Overall, PW Medtech Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's GF Score compare to ISRG and BDX?
PW Medtech Group's GF Score of 82 can be compared against companies in the Medical Devices & Instruments industry. Historically, PW Medtech Group's own GF Score has ranged from 31.00 to 93.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PW Medtech Group and its competitors. PW Medtech Group's current GF Score is 82, which is 28% above median its own 10-year median of 64.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current GF Score of 82. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 17.7% below its estimated fair value. The current GF Score is 82, which is 28% above median its 10-year median of 64.00. PW Medtech Group's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current GF Score is 82 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 17.7% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:PWE:
GF Score: 82 (28% above median its 10-year median of 64.00)
GF Value™: €0.13 vs. price of €0.11 (17.7% below fair value)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score
Get the complete analysis for FRA:PWE
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 